On May 17, 2022 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a neuroscience-focused biotechnology company developing next-generation, psychedelic-inspired mental health medicines, reported that Dr. Joseph Tucker, Chief Executive Officer of Enveric, will participate virtually in the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022 (Press release, Enveric Biosciences, MAY 17, 2022, https://www.enveric.com/news/enveric-biosciences-to-participate-in-the-h-c-wainwright-global-investment-conference-on-may-23-26-2022/ [SID1234614749]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Tucker’s corporate presentation will be available on-demand starting Tuesday, May 24th at 7:00 a.m. ET. Register to attend here.

For more information about the conference, or to schedule a one-on-one meeting with Enveric’s management team, please contact your appropriate H.C. Wainwright representative, or send an email to KCSA Strategic Communications at [email protected].

On May 17, 2022 Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, reported that Mr. Darren Lui, President and Executive Director of Aptorum Group will present virtually at the H.C. Wainwright Global Investment Conference being held on May 23-26, 2022 (Press release, Aptorum, MAY 17, 2022, View Source [SID1234614767]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aptorum Group management will be available and conducting online one-on-one meetings with institutional investors through the conference. To register for the conference, please visit: View Source

On May 17, 2022 OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, reported that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) meeting from June 3–7, 2022 in Chicago, IL (USA) (Press release, OBI Pharma, MAY 17, 2022, View Source [SID1234614782]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

These studies will be presented by the lead investigators of OBI Pharma’s first-in-class anti-Globo H cancer vaccine (Adagloxad Simolenin) and Antibody Drug Conjugate (OBI-999), and AKR1C3 targeting prodrug (OBI-3424).

"OBI Pharma is proud to have posters at ASCO (Free ASCO Whitepaper) highlighting the ongoing clinical trials with our first-in-class cancer therapeutics, Adagloxad Simolenin, OBI-999, and OBI-3424. We look forward to providing updates of our current clinical studies, which we believe could offer potential therapeutic benefits for patients whose cancer cells show Globo H or AKR1C3 expression. We are also excited to host an OBI Pharma exhibit booth to meet with investigators and meeting participants" stated Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma.

Poster / Abstract: TPS611
Title: A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer.
Session Title: Breast Cancer—Local/Regional/Adjuvant
Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
Session Date and Time: Monday, June 6, 2022. 8:00 a.m. – 11:00 a.m. Central Time

Poster / Abstract: 3029
Title: First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD, The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Central Time

Poster / Abstract: 3030
Title: Safety, Pharmacokinetics, and Clinical Activity of OBI-3424, an AKR1C3-Activated Prodrug, in Patients with Advanced or Metastatic Solid Tumors: A Phase 1 Dose-Escalation Study
Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Presenter: Apostolia Maria Tsimberidou PhD, MD,The University of Texas MD Anderson Cancer Center, Houston, TX.
Session Date and Time: Sunday, June 5, 2022. 8:00 a.m. – 11:00 a.m. Eastern Time

The above poster presentations will be available online at www.obipharma.com on June 6, 2022.

OBI Exhibit Booth # 3144 (McCormick Center, Chicago, IL).
OBI Pharma personnel will be available to discuss our Cancer pipeline under clinical development for ASCO (Free ASCO Whitepaper) meeting attendees only from June 6-8 from 9am to 5 pm CST.

On May 17, 2022 MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products for people living with endocrine and orphan lung diseases, reported that it has entered into an agreement with Zealand Pharma A/S (Nasdaq: ZEAL) to acquire V-Go for $10 million, with additional sales-based milestones plus the cost of certain inventory (Press release, Mannkind, MAY 17, 2022, View Source [SID1234614717]). The acquisition of V-Go allows MannKind to expand its portfolio and strengthen its commitment to providing innovative mealtime diabetes solutions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"MannKind is passionate about being a leader in mealtime control to address this unmet need within the diabetes community," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "This acquisition strategically leverages our infrastructure in the diabetes space and positions MannKind’s endocrine business for additional growth."

"This transaction is an important step forward in executing on the strategic changes we announced at the end of March, to find partners for our commercial products and refocus our priorities on R&D," said Adam Steensberg, MD, Chief Executive Officer of Zealand Pharma. "We believe we have found the right partner to fully leverage the value of V-Go and ensure continued availability of the product by patients and prescribers."

V-Go is a once-daily, wearable, insulin delivery device that helps provide blood sugar control for everyday lifestyles. Designed to be patient-friendly, V-Go is worn like a patch and eliminates the need for taking multiple daily shots.

"The easy click-and-go mechanism of V-Go and its ability to be flexibly placed on your body each day aligns with our mission of providing products that allow patients living with diabetes to experience life without limits," said Alejandro Galindo, Executive Vice President, Endocrine Business Unit for MannKind Corporation. "V-Go joins our ultra rapid-acting inhaled insulin product, Afrezza, in expanding MannKind’s portfolio of products that change the way diabetes is treated."

The acquisition of V-Go by MannKind is anticipated to close in May 2022, subject to the satisfaction of certain closing conditions.

On May 17, 2022 Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported that Jounce management will participate at the following upcoming investor conferences (Press release, Jounce Therapeutics, MAY 17, 2022, View Source [SID1234614750]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright Global Investment Conference: Presentation will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. ET.
Cowen’s 3rd Annual Oncology Innovation Summit: Insights for ASCO (Free ASCO Whitepaper) & EHA (Free EHA Whitepaper): A live presentation will take place virtually on Thursday, June 2, 2022 at 1:30 p.m. ET.
A webcast of each presentation can be accessed by visiting the Investors & Media section of Jounce’ website at View Source A replay of each webcast will be archived on Jounce’s site for 30 days following the event.